Investor Relations
PharmChem, Inc. common stock is traded on the OTC/Pink Sheets under the symbol 'PCHM.PK'. On March 26, 2004, the Company filed Form 15 under Rule 12g-2 of the 1934 Securities Exchange Act, whereby all reports required to be filed by Section 13(a) - including Forms 10-K, 10-Q & 8-K - are immediately suspended. As a result, the Company does not submit financial and other reports to the Securities and Exchange Commission.
Our CUISP number is 717133
Our Transfer Agent is Transfer Online at http://transferonline.com
Phone: (503) 227 2950 Fax: (503) 227 6874
Disclosure Page on OTC Markets: https://www.otcmarkets.com/stock/PCHM/disclosure
PharmChem, Inc. Company Contacts:
Thompson Clark- Interim CEO/Director
Kerri Wagner - Chief Revenue Officer kwagner@pharmchem.com
Shana Veale - VP & CFO sveale@pharmchem.com
Tim Eriksen - Chairman of the Board
Thompson Clark - Director
James Ford - Director
Phone: 855-458-4100
Email: info@pharmchem.com
2411 E. Loop 820 N. Fort Worth, TX 76118
2023
- 12/31/23 Q4 Financial Statements + Letter to Shareholders and OTCIQ Disclosure
- 11/2/23 Q3 Financial Statements + Letter to Shareholders and OTCIQ Disclosure
- 8/31/23 Chairman Tice Brown Final Letter to Shareholders
- 7/26/23 Q2 Financial Statements + Letter to Shareholders and OTCIQ Disclosure
- 7/12/23 - 2023 Proxy Statement
- 4/26/23 Q1 Financial Statements + Letter to Shareholders and OTCIQ Disclosure
2022
- Annual Report - 2022 Financial Statement Audit with Auditor Letter
- 12/31/2022 Q4 Financial Statements + Letter to Shareholders and OTCIQ Disclosure
- 10/24/22 Q3 Financial Statements + Letter to Shareholders and OTCIQ Disclosure
- 8/31/2022 Shareholder Meeting Q&A
- 7/27/22 PharmChem Q2 Letter to Shareholders
- 4/22/22 Q1 Financial Statements + Letter to Shareholders and OTCIQ Disclosure
2021
- 12/31/21 Letter to Shareholders + Unaudited Q4 Financials
- 9/30/21 Letter to Shareholders
- 6/30/21 Letter to Shareholders